Navigation Links
Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
Date:2/28/2008

icted cash and marketable securities totaled $71.0 million, compared to $64.1 million at December 31, 2006. Cash used in operating activities was $34.7 million for the year ended December 31, 2007.

"Today, Kosan announced a reprioritization of its clinical development portfolio to focus resources on product candidates with the highest near-term therapeutic potential and commercial value for the company," said Helen S. Kim, Kosan's President and Chief Business Officer. "Kosan's top priorities in 2008 are the advancement of the tanespimycin TIME program in multiple myeloma and the tanespimycin metastatic breast cancer clinical program, and the development of epothilone KOS-1584, which is entering Phase 2 in non-small cell lung cancer. We believe that focusing our resources and efforts on these promising later-stage programs now will bring the most benefit to Kosan and its shareholders in the near-term and support our ability to utilize our resources most effectively and to invest in those high-value programs that will be the key value drivers of our company. We enter 2008 with renewed focus, resolve and confidence in our ability to successfully transform these product candidates into meaningful commercial opportunities for our company."

2008 Financial Outlook

Kosan's outlook for 2008 excludes any potential collaborations, strategic alliances or financings Kosan may conclude this year. The Company anticipates that cash used in operating activities will be in the range of $40 million to $50 million.

Conference Call and Webcast Today

Simultaneous with this announcement of Kosan's fourth quarter and full year 2007 financial results, Kosan also announced a reprioritization of its clinical portfolio. Kosan will hold a conference call and webcast today to discuss both of these announcements. Access information is as follows:

Kosan will hold a conference call to discuss the Company's fourth quarter and full year 2007 financial results
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Kosan Announces February 28, 2008 Conference Call and Webcast
2. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
3. Kosan Announces Third Quarter 2007 Financial Results
4. Kosan to Reacquire Epothilone Program From Roche
5. Kosan Biosciences to Host Research & Development Day on October 31, 2007
6. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
7. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
8. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
9. Wyeth Announces Executive Change in Finance Organization
10. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
11. Pharmacopeia Announces Management Team Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Hall effect in bilayer graphene and shown that this ... electric field. , The fractional quantum Hall effect, ... are exposed to large magnetic fields, is a striking ... behave as a single system. However, while the basic ... of this collective behavior remain not well understood, in ...
(Date:7/10/2014)... out for crude 3-D glasses, polarized glasses, and ... basic devices, used to trick the brain into ... rendered obsolete with the introduction of new holography ... TAU doctoral students Yuval Yifat, Michal Eitan, and ... on nanoantennas that could be used for security ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
(Date:1/15/2014)... PA (PRWEB) January 15, 2014 The Pittcon ... publisher of Food Safety Tech , an e-Journal and ... signed an agreement for the second year for the co-location ... Pittcon 2014. The partnership provides that the registration fee to ...
Breaking Biology Technology:Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3Layered security: Carbon nanotubes promise improved flame-resistant coating 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3
... Disease Altering Treatment Shows Ability to Prevent HIV ... VIRxSYS Corporation, a,privately held company developing gene therapies ... Phase II trial of VRX496, a gene,therapy for ... Conference on,Retroviruses and Opportunistic Infections (CROI) in Boston, ...
... Strengthening PPD,s presence in Eastern Europe, WILMINGTON, N.C., ... has signed an agreement to purchase InnoPharm,Ltd., an independent ... acquisition will expand PPD,s global reach with,established offices in ... CROs in Russia, InnoPharm was a pioneer in the,implementation ...
... (Nasdaq: IDIX ) announced today that Idenix management,will ... & Investor,Conference on Tuesday, February 12, 2008 at 9:30 ... the Waldorf-Astoria Hotel in New York, NY., The ... accessed,under "Calendar of Events" in the Idenix Investor Center ...
Cached Biology Technology:VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2PPD to Acquire InnoPharm Ltd. 2PPD to Acquire InnoPharm Ltd. 3
(Date:7/10/2014)... New York , July 7, 2014 ... by Transparency Market Research "Electronic Access Control Systems Market ... 2014 - 2019," the global Electronic Access Control systems ... and is expected to grow at a CAGR of ... value of USD 31,187.8 million in 2019. ...
(Date:7/10/2014)... belongs to the large, mainly tropical flowering plant family ... in the family rely on bees for their pollination. Only ... or vertebrates. The flowers of Axinaea appear in ... petals of the different species are pink, yellow, orange or ... the contrasting colours of their bulbous appendages. The pollination mechanism ...
(Date:7/10/2014)... has helped stabilize or even improve the state ... the situation in the Mediterranean has deteriorated over ... evaluating nine fish species reported in the Cell ... 10, scientists call for stringent monitoring of Mediterranean ... advanced management plans in Mediterranean waters. , Their ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5Novel type of bird pollination mechanism discovered in South America 2Mediterranean fish stocks show steady decline 2
... 20, 2013 Market news updates for advancing ... Inc. (OTCQB: NXTD), Apple Inc. (NASDAQ: AAPL ), ... CSCO ) and NQ Mobile Inc. (NYSE: NQ) ... published a report on NXT-ID, Inc., (OTCQB: NXTD) featuring the ...
... of all humans are persistently colonized with Staphylococcus aureus ... of the major sources of hospital-acquired infections, including the antibiotic-resistant ... discovered one of the keys to the immense success of ... immune defense mechanism and use it to destroy white blood ...
... fattening than others? What about the risks of bariatric ... (ASN) on December 5-7 for answers to these questions ... Nutrition Conference. The 3-day program delivers valuable ... satellite sessions, and networking opportunities. Credentialed media, science writers ...
Cached Biology News:Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential 2Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential 3Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential 4Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential 5Staphylococcus aureus bacteria turns immune system against itself 2Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 2
...
... Antibody Validation Service enables early selection ... development by providing quantitative data for ... of each antibody. Furthermore quantitative antibody ... off-target activity of your antibodies., The ...
... western blotting. Get results sooner and save hours ... detection. Eliminates the need for a membrane transfer ... reagents are ready-to-use. No reagents to prepare or ... reagents required. Guarantees a simple to perform, mistake-free ...
... paper sandwiches are composed of a precut ... thick filter paper that are preassembled into ... These 7 x 8.5 cm membrane sandwiches ... Gel-sized gels and are supplied as a ...
Biology Products: